Keith Katkin

Consultant to the Board of Directors at Urovant Sciences, Inc.

Keith Katkin is a seasoned executive in the biopharmaceutical industry with extensive experience in leadership roles and board positions. He currently serves as a Board Member at Emergent BioSolutions Inc., where he is a member of the Compensation Committee and the Nominating and Corporate Governance Committee, as well as the Chair of the Special Transactions Committee.3

Career Highlights

Katkin has held several notable positions throughout his career:

Chief Executive Officer and Board Member of Urovant Sciences Ltd. from September 2017 to March 2020.1 2
President and CEO of Avanir Pharmaceuticals, Inc. from 2007 to 2016, where he led the company's growth and its eventual sale to Otsuka Pharmaceutical Co., Ltd. for $3.5 billion.1 2
Vice President of Commercial Development at Peninsula Pharmaceuticals, Inc., where he played a key role in the company's IPO and sale to Johnson & Johnson.1

Current Board Positions

In addition to his role at Emergent BioSolutions, Katkin serves on the boards of:

Eledon Pharmaceuticals, Inc. (Chairman)1 2
Syndax Pharmaceuticals, Inc.1 2

Education and Qualifications

Keith Katkin holds the following credentials:

M.B.A. from the Anderson School of Business at UCLA1 2
B.S. in Business and Accounting from Indiana University1 2
Licensed Certified Public Accountant1 2

Industry Experience

Throughout his career, Katkin has gained valuable experience in various aspects of the biopharmaceutical industry, including:

Commercial development
Sales and marketing
Executive leadership
Mergers and acquisitions
Initial public offerings

His diverse background spans roles at companies such as InterMune, Amgen, and Abbott Laboratories.1 2

Keith Katkin's LinkedIn profile confirms his current position as a Board Member at Emergent BioSolutions4, reflecting his ongoing involvement in the biopharmaceutical industry and corporate governance.